Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Public research footprint of Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, compiled from the ClinicalTrials.gov public registry.

128

Registered studies

Active

Recruiting now

Completed

Stopped or withdrawn

Most-studied conditions

Recurrent Rhabdoid Tumor · Recurrent B Acute Lymphoblastic Leukemia · Recurrent Malignant Germ Cell Tumor · Refractory Rhabdoid Tumor

Recently updated registry entries

NCT07438496 — A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus (Recruiting)
NCT07218029 — A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension… (Recruiting)
NCT02567435 — Combination Chemotherapy With or Without Temsirolimus in Treating Patients With… (Active Not Recruiting)

Work at Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 02, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.